IDEXX Announces Novel Diagnostic Test for Kidney Injury, Expanding the Veterinary Industry’s Most Comprehensive Renal Testing Portfolio

IDEXX Laboratories, Inc.  a global leader in pet healthcare innovation, today announced the launch of the first veterinary diagnostic test for detecting kidney injury in cats and dogs. According to a recent IDEXX survey, as many as one-third of kidney cases seen by veterinarians are related to kidney injury, and a diagnosis can be challenging due to subtle or nonspecific signs.1 The IDEXX Cystatin B Test will be included in test panels assessing renal health, uncovering new clinical insights for an estimated two million patient visits annually. These tests will be run at IDEXX Reference Laboratories starting later this year in the U.S. and Canada, with plans to introduce the test in Europe in 2024.

The kidneys are vital to the overall health of a patient, regulating blood pressure, electrolyte balance, and red blood cell production, and removing toxins. IDEXX SDMA testing provides veterinarians with unmatched insights into kidney function, and the IDEXX Cystatin B Test will enhance their view into kidney health by detecting injury and providing additional clarity when a change in kidney function may not be apparent. Together, the IDEXX Cystatin B and IDEXX SDMA® tests offer a comprehensive view of the kidneys by uncovering structural injury and impaired kidney function.


« With the addition of the IDEXX Cystatin B Test, we are pleased to offer the industry’s first biomarker for kidney injury, » said Jay Mazelsky, IDEXX President and Chief Executive Officer. « The IDEXX portfolio of tests and technologies enables veterinarians to intervene earlier, advance treatment, and now detect kidney injury, resulting in better outcomes throughout the lives of their patients. »

The IDEXX expanded renal testing portfolio now includes:

  • IDEXX Cystatin B Test, detecting kidney injury with or without changes in kidney function, providing valuable insights in cases such as early toxin exposure.
  • IDEXX SDMA® Test and creatinine, helping to establish a baseline for kidney function for monitoring and early kidney disease detection.
  • IDEXX FGF-23 Test, allowing for more confident recommendations of targeted therapy for cats diagnosed with chronic kidney disease (CKD) by monitoring phosphorous overload.
  • Urine testing, providing a deeper understanding of total kidney health by examining the physical and chemical properties of urine.

For more information on the IDEXX Cystatin B Test and IDEXX kidney health solutions, please visit IDEXX Cystatin B.

A joint statement from three founding members of the American College of Veterinary Nephrology and Urology accentuates the value this novel biomarker holds in the industry and aligns with a recent statement from the International Renal Interest Society (IRIS):

« The advent of diagnostic biomarkers capable to detect the presence of acute kidney injury as well as active and ongoing kidney injury in advance of or in the absence of changes in conventional markers of kidney function forecast an important advance in the evaluation of acute and chronic kidney disease in dogs. The development and validation of Cystatin-B as an active kidney injury biomarker in dogs that will be readily available to veterinarians has the potential to reshape the future diagnostic and therapeutic directions of kidney disease. As nephrologists, we anxiously await this new era of early disease discovery and management. »

Source :

Laisser un commentaire

Votre adresse e-mail ne sera pas publiée. Les champs obligatoires sont indiqués avec *

Ce site utilise Akismet pour réduire les indésirables. En savoir plus sur comment les données de vos commentaires sont utilisées.

Articles récents

Suivez-nous sur les réseaux sociaux